JP2022548031A5 - - Google Patents

Info

Publication number
JP2022548031A5
JP2022548031A5 JP2022516060A JP2022516060A JP2022548031A5 JP 2022548031 A5 JP2022548031 A5 JP 2022548031A5 JP 2022516060 A JP2022516060 A JP 2022516060A JP 2022516060 A JP2022516060 A JP 2022516060A JP 2022548031 A5 JP2022548031 A5 JP 2022548031A5
Authority
JP
Japan
Prior art keywords
item
protein
sequence
composition according
target gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548031A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050491 external-priority patent/WO2021050940A1/en
Publication of JP2022548031A publication Critical patent/JP2022548031A/ja
Publication of JP2022548031A5 publication Critical patent/JP2022548031A5/ja
Pending legal-status Critical Current

Links

JP2022516060A 2019-09-13 2020-09-11 脂質ナノ粒子によって送達されるcrispr/casシステムを使用する動物における転写調節 Pending JP2022548031A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900080P 2019-09-13 2019-09-13
US62/900,080 2019-09-13
US202063042762P 2020-06-23 2020-06-23
US63/042,762 2020-06-23
PCT/US2020/050491 WO2021050940A1 (en) 2019-09-13 2020-09-11 Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles

Publications (2)

Publication Number Publication Date
JP2022548031A JP2022548031A (ja) 2022-11-16
JP2022548031A5 true JP2022548031A5 (https=) 2023-09-08

Family

ID=72659909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516060A Pending JP2022548031A (ja) 2019-09-13 2020-09-11 脂質ナノ粒子によって送達されるcrispr/casシステムを使用する動物における転写調節

Country Status (8)

Country Link
US (1) US20210079394A1 (https=)
EP (1) EP4028063A1 (https=)
JP (1) JP2022548031A (https=)
KR (1) KR20220062079A (https=)
CN (1) CN114616002A (https=)
AU (1) AU2020346056A1 (https=)
CA (1) CA3153980A1 (https=)
WO (1) WO2021050940A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
WO2022232442A2 (en) * 2021-04-28 2022-11-03 Salk Institute For Biological Studies Multiplex crispr/cas9-mediated target gene activation system
US20240415980A1 (en) * 2021-10-28 2024-12-19 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
CA3237303A1 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
KR20240117571A (ko) 2021-12-08 2024-08-01 리제너론 파마슈티칼스 인코포레이티드 돌연변이 마이오실린 질환 모델 및 이의 용도

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS501B1 (https=) 1970-05-19 1975-01-06
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
US9234213B2 (en) * 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
JP6793547B2 (ja) * 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
ES2788426T3 (es) 2014-06-16 2020-10-21 Univ Johns Hopkins Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
WO2016049258A2 (en) * 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
WO2016106121A1 (en) 2014-12-23 2016-06-30 Syngenta Participations Ag Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
WO2016149484A2 (en) 2015-03-17 2016-09-22 Temple University Of The Commonwealth System Of Higher Education Compositions and methods for specific reactivation of hiv latent reservoir
WO2016197133A1 (en) * 2015-06-04 2016-12-08 Protiva Biotherapeutics, Inc. Delivering crispr therapeutics with lipid nanoparticles
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US11279928B2 (en) * 2015-06-29 2022-03-22 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
US12110490B2 (en) * 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
LT3436077T (lt) * 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
EP3445853A1 (en) * 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
SG10202106058WA (en) 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
WO2018112320A1 (en) * 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
WO2019067910A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
US20190098879A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use

Similar Documents

Publication Publication Date Title
JP2022548031A5 (https=)
Landmesser et al. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Bauman et al. Therapeutic potential of splice-switching oligonucleotides
AU2016331084B2 (en) Compositions and methods for inhibiting gene expression of LPA
Järver et al. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA
JP3316216B2 (ja) 安定化外部ガイド配列
Mann et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Rudolph et al. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells
Chuah et al. Self-assembled peptide-based system for mitochondrial-targeted gene delivery: functional and structural insights
Lindley et al. Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies
KR20160097331A (ko) 뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도
JP2020513783A (ja) Crispr
JP2019503716A (ja) Crisprcpf1の結晶構造
AU2014361834A1 (en) CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
Raguraman et al. Antisense oligonucleotide-mediated splice switching: potential therapeutic approach for cancer mitigation
JP2021525508A (ja) 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法
CN107548401A (zh) 用于细胞内递送分子的肽和纳米颗粒
Zhao et al. The development and improvement of ribonucleic acid therapy strategies
CN119095972B (zh) 基因组编辑的组合物和方法
TW202333747A (zh) 調節pcsk9之方法及其用途
Ma et al. I-motif-based in situ bipedal hybridization chain reaction for specific activatable imaging and enhanced delivery of antisense oligonucleotides
Kim et al. Dually stabilized triblock copolymer micelles with hydrophilic shell and hydrophobic interlayer for systemic antisense oligonucleotide delivery to solid tumor
Juliano Intracellular delivery of oligonucleotide conjugates and dendrimer complexes
Svenson et al. Tumor selective silencing using an RNAi-conjugated polymeric nanopharmaceutical
JP2024533316A (ja) ゲノムを調節するための方法及び組成物